The mechanisms of acute transplant rejection revisited

Journal of Nephrology

Volumn 25, Issue 2, 2012, Pages 150-158

  Ponticelli, Claudio ^a  

^a Humanitas Institute   (Italy)

Author keywords

Acute rejection; Antibody mediated rejection; Antigen recognition; Dendritic cells; Innate immunity

Indexed keywords

ALLOANTIGEN; B LYMPHOCYTE RECEPTOR; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 3; MAMMALIAN TARGET OF RAPAMYCIN; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; PENTRAXIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TRANSCRIPTION FACTOR NFAT;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; ARTICLE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN SYNTHESIS; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ANIMALS; ANTIBODIES; DENDRITIC CELLS; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; KIDNEY TRANSPLANTATION; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 84863327242     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/jn.5000048     Document Type: Article

References (101)

1. MHC Sequencing Consortium. Complete sequence and gene map of a human major histocompatibility complex. The MHC sequencing consortium. Nature. 1999;401(6756):921-923.
2. Hassan MI, Ahmad F. Structural diversity of class I MHC-like molecules and its implications in binding specificities. Adv Protein Chem Struct Biol. 2011;83:223-270.
3. Marsh SG, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens. 2005;65(4): 301-369.
4. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice: Part I: morphology, quantitation, tissue distribution. J Exp Med. 1973;137(5):1142-1162.
5. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol. 2010;108: 111-165.
6. von Andrian UH, Mackay CR. T-cell function and migration: two sides of the same coin. N Engl J Med. 2000;343(14): 1020-1034.
7. Mueller DL, Jenkins MK, Schwartz RH. An accessory cell-derived costimulatory signal acts independently of protein kinase C activation to allow T cell proliferation and prevent the induction of unresponsiveness. J Immunol. 1989;142(8):2617-2628.
8. Crabtree GR. Contingent genetic regulatory events in T lymphocyte activation. Science. 1989;243(4889):355-361.
9. Whitelegg A, Barber LD. The structural basis of T-cell allorecognition. Tissue Antigens. 2004;63(2):101-108.
10. Golshayan D, Pascual M. Tolerance-inducing immunosuppressive strategies in clinical transplantation: an overview. Drugs. 2008;68(15):2113-2130.
11. Safinia N, Afzali B, Atalar K, Lombardi G, Lechler RI. T-cell alloimmunity and chronic allograft dysfunction. Kidney Int. 2010;78(suppl 1119):S2-S12.
12. Akira S. TLR signaling. Curr Top Microbiol Immunol. 2006;311:1-16.
13. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135-145.
14. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499-511.
15. Yamamoto M, Sato S, Hemmi H, et al. TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway. Nat Immunol. 2003;4(11): 1144-1150.
16. Shigeoka AA, Holscher TD, King AJ, et al. TLR2 is constitutively expressed within the kidney and participates in ischemic renal injury through both MyD88-dependent and-independent pathways. J Immunol. 2007;178(10):6252-6258.
17. West AP, Shadel GS, Ghosh S. Mitochondria in innate immune responses. Nat Rev Immunol. 2011;11(6):389-402.
18. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12(1):991-1045.
19. Land WG. The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation. 2005;79(5):505-514.
20. Obhrai J, Goldstein DR. The role of toll-like receptors in solid organ transplantation. Transplantation. 2006;81(4):497-502.
21. Rosin DL, Okusa MD. Dangers within: DAMP responses to damage and cell death in kidney disease. J Am Soc Nephrol. 2011;22(3):416-425.
22. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol. 2008;8(4):279-289.
23. Alegre ML, Goldstein DR, Chong AS. Toll-like receptor signaling in transplantation. Curr Opin Organ Transplant. 2008;13(4): 358-365.
24. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009; 114(12):2367-2374.
25. Li K, Fazekasova H, Wang N, et al. Expression of complement components, receptors and regulators by human dendritic cells. Mol Immunol. 2011;48(9-10):1121-1127.
26. Damman J, Hoeger S, Boneschansker L, et al. Targeting complement activation in brain-dead donors improves renal function after transplantation. Transpl Immunol. 2011;24(4): 233-237.
27. Damman J, Daha MR, van Son WJ, Leuvenink HG, Ploeg RJ, Seelen MA. Crosstalk between complement and Toll-like receptor activation in relation to donor brain death and renal ischemia-reperfusion injury. Am J Transplant. 2011;11(4): 660-669.
28. Naesens M, Li L, Ying L, et al. Expression of complement components differs between kidney allografts from living and deceased donors. J Am Soc Nephrol. 2009;20(8): 1839-1851.
29. Castellano G, Melchiorre R, Loverre A, et al. Therapeutic targeting of classical and lectin pathways of complement protects from ischemia-reperfusion-induced renal damage. Am J Pathol. 2010;176(4):1648-1659.
30. Peng Q, Li K, Wang N, et al. Dendritic cell function in allostimulation is modulated by C5aR signaling. J Immunol. 2009;183(10):6058-6068.
31. Zhou W, Farrar CA, Abe K, et al. Predominant role for C5b-9 in renal ischemia/reperfusion injury. J Clin Invest. 2000; 105(10):1363-1371.
32. Paust S, von Andrian UH. Natural killer cell memory. Nat Immunol. 2011;131(6):500-508.
33. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. 2008;9(5): 503-510.
34. Vincenti F, Larsen C, Durrbach A, et al; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N Engl J Med. 2005;353(8):770-781.
35. Wasowska BA. Cross-talk between innate and adaptive immune responses in infection, transplant and autoimmune models. Curr Opin Organ Transplant. 2011;16(1):1-6.
36. Miller DM, Rossini AA, Greiner DL. Role of innate immunity in transplantation tolerance. Crit Rev Immunol. 2008;28(5): 403-439.
37. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med. 2004;351(26):2715-2729.
38. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369(6483):756-758.
39. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110(2):163-175.
40. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110(2):177-189.
41. Wang L, Rhodes CJ, Lawrence JC Jr. Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1. J Biol Chem. 2006;281(34):24293-24303.
42. Quéméneur L, Gerland LM, Flacher M, Ffrench M, Revillard JP, Genestier L. Differential control of cell cycle, proliferation, and survival of primary T lymphocytes by purine and pyrimidine nucleotides. J Immunol. 2003;170(10):4986-4995.
43. Mills KH. Induction, function and regulation of IL-17-producing T cells. Eur J Immunol. 2008;38(10):2636-2649.
44. Hanidziar D, Koulmanda M. Inflammation and the balance of Treg and Th17 cells in transplant rejection and tolerance. Curr Opin Organ Transplant. 2010;15(4):411-415.
45. Gorantla VS, Schneeberger S, Brandacher G, et al. T regulatory cells and transplantation tolerance. Transplant Rev (Orlando). 2010;24(3):147-159.
46. Chadha R, Heidt S, Jones ND, Wood KJ. Th17: contributors to allograft rejection and a barrier to the induction of transplantation tolerance? Transplantation. 2011;91(9):939-945.
47. Constant SL. B lymphocytes as antigen presenting cells for CD4+ T cell priming in vivo. J Immunol. 1999;16:382-387.
48. Ng YH, Oberbarnscheidt MH, Chandramoorthy HC, Hoffman R, Chalasani G. B cells help alloreactive T cells differentiate into memory T cells. Am J Transplant. 2010;10(9):1970-1980.
49. Vivier E, Raulet DH, Moretta A, et al. Innate or adaptive immunity? The example of natural killer cells. Science. 2011; 331(6013):44-49.
50. Benichou G, Yamada Y, Yun SH, Lin C, Fray M, Tocco G. Immune recognition and rejection of allogeneic skin grafts. Immunotherapy. 2011;3(6):757-770.
51. Liu W, Li XC. An overview on non-T cell pathways in transplant rejection and tolerance. Curr Opin Organ Transplant. 2010;15(4):422-426.
52. Molesworth-Kenyon SJ, Oakes JE, Lausch RN. A novel role for neutrophils as a source of T cell-recruiting chemokines IP-10 and Mig during the DTH response to HSV-1 antigen. J Leukoc Biol. 2005;77(4):552-559.
53. Segerer S, Nelson PJ. Chemokines in renal diseases. Scientific World Journal. 2005;5:835-844.
54. Asgari E, Zhou W, Sacks S. Complement in organ transplantation. Curr Opin Organ Transplant. 2010;15(4):486-491.
55. Sacks SH, Chowdhury P, Zhou W. Role of the complement system in rejection. Curr Opin Immunol. 2003;15(5): 487-492.
56. Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med. 2002;8(6):582-587.
57. Bottazzi B, Garlanda C, Salvatori G, Jeannin P, Manfredi A, Mantovani A. Pentraxins as a key component of innate immunity. Curr Opin Immunol. 2006;18(1):10-15.
58. Inforzato A, Jaillon S, Moalli F, et al. The long pentraxin PTX3 at the crossroads between innate immunity and tissue remodelling. Tissue Antigens. 2011;77(4):271-282.
59. Nauta AJ, de Haij S, Bottazzi B, et al. Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int. 2005;67(2):543-553.
60. Du Clos TW, Mold C. Pentraxins (CRP, SAP) in the process of complement activation and clearance of apoptotic bodies through Fcttreceptors. Curr Opin Organ Transplant. 2011;16(1):15-20.
61. Oliveira G, Xavier P, Sampaio SN, Alves H. Thymoglobulin down-regulates pentraxin 3 synthesis that correlates with acute rejection on kidney transplant patients. Tissue Antigens. 2010;75:594-595.
62. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417-426.
63. Gonçalves GM, Castoldi A, Braga TT, Câmara NO. New roles for innate immune response in acute and chronic kidney injuries. Scand J Immunol. 2011;73(5):428-435.
64. Kumar H, Kumagai Y, Tsuchida T, et al. Involvement of the NLRP3 inflammasome in innate and humoral adaptive immune responses to fungal beta-glucan. J Immunol. 2009; 183(12):8061-8067.
65. Dunne A, Ross PJ, Pospisilova E, et al. Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol. 2010;185(3):1711-1719.
66. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant. 2005;5(11):2611-2618.
67. Colvin RB, Hirohashi T, Farris AB, Minnei F, Collins AB, Smith RN. Emerging role of B cells in chronic allograft dysfunction. Kidney Int Suppl. 2010;78(119):S13-S17.
68. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cellmediated rejection. Clin Exp Immunol. 1991;86(3):464-470.
69. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol. 2001;12(3):574-582.
70. Regele H, Böhmig GA, Habicht A, et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol. 2002;13(9):2371-2380.
71. Feucht HE. Complement C4d in graft capillaries: the missing link in the recognition of humoral alloreactivity. Am J Transplant. 2003;3(6):646-652.
72. Racusen LC, Colvin RB, Solez K, et al. Antibody-mediated rejection criteria: an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant. 2003;3(6):708-714.
73. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8(4):753-760.
74. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation. 2009;87(11):1681-1688.
75. Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation. 2009;88(4):568-574.
76. Hidalgo LG, Campbell PM, Sis B, et al. De novo donor-specific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9(11):2532-2541.
77. Zeevi A, Lunz JG III, Shapiro R, et al. Emerging role of donorspecific anti-human leukocyte antigen antibody determination for clinical management after solid organ transplantation. Hum Immunol. 2009;70(8):645-650.
78. Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation. 2011;91(10):1103-1109.
79. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol. 2007;18(4): 1046-1056.
80. Platt JL. Antibodies in transplantation. Discov Med. 2010; 10(51):125-133.
81. Bradley JA, Baldwin WM, Bingaman A, et al. Antibody-mediated rejection: an ounce of prevention is worth a pound of cure. Am J Transplant. 2011;11(6):1131-1139.
82. Willicombe M, Brookes P, Santos-Nunez E, et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant. 2011;11(3):470-477.
83. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21(8):1398-1406.
84. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant. 2011;11(5):896-906.
85. Loupy A, Suberbielle-Boissel C, Zuber J, et al. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation. 2010;89(11):1403-1410.
86. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation. 2010;89(9):1095-1102.
87. Shehata N, Palda V, Bowen T, et al. The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline. Transfus Med Rev. 2010; 24(Suppl 1):S28-S50.
88. Gloor JM, Lager DJ, Fidler ME, et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation. 2005;80(11): 1572-1577.
89. Genberg H, Kumlien G, Wennberg L, Berg U, Tydén G. ABOincompatible kidney transplantation using antigen-specific immunoadsorption and rituximab: a 3-year follow-up. Transplantation. 2008;85(12):1745-1754.
90. Ichimaru N, Takahara S. Japan's experience with living-donor kidney transplantation across ABO barriers. Nat Clin Pract Nephrol. 2008;4(12):682-692.
91. Clatworthy MR. Targeting B cells and antibody in transplantation. Am J Transplant. 2011;11(7):1359-1367.
92. Lucas JG, Co JP, Nwaogwugwu UT, Dosani I, Sureshkumar KK. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother. 2011;12(4):579-592.
93. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation. 2011;91(11): 1218-1226.
94. Newell KA, Asare A, Kirk AD, et al; Immune Tolerance Network ST507 Study Group. Identification of a B cell signature associated with renal transplant tolerance in humans. J Clin Invest. 2010;120:1836-1847.
95. Pallier A, Hillion S, Danger R, et al. Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. Kidney Int. 2010;78(5):503-513.
96. Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med. 2005;352(6):558-569.
97. Le Bas-Bernardet S, Hourmant M, Coupel S, Bignon JD, Soulillou JP, Charreau B. Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant. 2003;3(2):167-177.
98. Ismail AM, Badawi RM, El-Agroudy AE, Mansour MA. Pretransplant detection of anti-endothelial cell antibodies could predict renal allograft outcome. Exp Clin Transplant. 2009;7(2): 104-109.
99. Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int. 2011;79(6):655-662.
100. Regele H. Non-HLA antibodies in kidney allograft rejection: convincing concept in need of further evidence. Kidney Int. 2011;79(6):583-586.
101. Dragun D, Hegner B. Non-HLA antibodies post-transplantation: clinical relevance and treatment in solid organ transplantation. Contrib Nephrol. 2009;162:129-139.